Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Brendan M. Finnerty, Rasa Zarnegar, Irene M. Min, Yi-Chieh Nancy Du, Olivier Elemento, Zhengming Chen, Akanksha Verma, Marco Seandel, Anna Aronova, Dean P. Edwards, Theresa Scognamiglio, Maureen D. Moore, Shixia Huang, Thomas J. Fahey
Publikováno v:
Endocrine-Related Cancer. 26:411-423
Loss of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) expression by CpG promoter hypermethylation is associated with metastasis in gastroenteropancreatic neuroendocrine tumors; however, the mechanism of how UCHL1 loss contributes to metastatic pot
Autor:
C. Benedikt Westphalen, Annelore Altendorf-Hofmann, Katharina Brüwer, Jens Werner, Thomas Kirchner, Stefan Boeck, Volker Heinemann, Florian Bösch, Gabriele Schubert-Fritschle, Christoph J. Auernhammer, Martin K. Angele, Christine Spitzweg, Thomas Knösel
Publikováno v:
Endocrine-Related Cancer. 26:293-301
Cancer immunotherapy has evolved major breakthroughs in the last years. The cell-surface receptor programmed death-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1), have been detected in various cancer types. However, the analysis on gastro
Autor:
Andrew Weaver, Anja Rinke, Esben Andreas Carlsen, Halfdan Sorbye, Peter Oturai, Wouter T Zandee, Simona Grozinsky-Glasberg, Hojjat Ahmadzadehfar, Amichay Meirovitz, Jarosław B. Ćwikła, Chiara Maria Grana, Anne Kirstine Arveschoug, Dan Granberg, Nicola Fazio, Ulrich Knigge, Martin A. Walter, Sara Gritti, Andrea Frilling
Publikováno v:
Endocrine-Related Cancer
Carlsen, E A, Fazio, N, Granberg, D, Grozinsky-Glasberg, S, Ahmadzadehfar, H, Grana, C M, Zandee, W T, Cwikla, J, Walter, M A, Oturai, P S, Rinke, A, Weaver, A, Frilling, A, Gritti, S, Arveschoug, A K, Meirovitz, A, Knigge, U & Sorbye, H 2019, ' Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : A multicenter cohort study ', Endocrine-Related Cancer, vol. 26, no. 2, pp. 227-239 . https://doi.org/10.1530/ERC-18-0424
Carlsen, E A, Fazio, N, Granberg, D, Grozinsky-Glasberg, S, Ahmadzadehfar, H, Grana, C M, Zandee, W T, Cwikla, J, Walter, M A, Oturai, P S, Rinke, A, Weaver, A, Frilling, A, Gritti, S, Arveschoug, A K, Meirovitz, A, Knigge, U & Sorbye, H 2019, ' Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : a multicenter cohort study ', Endocrine-Related Cancer, vol. 26, no. 2, pp. 227-239 . https://doi.org/10.1530/ERC-18-0424
Endocrine-Related Cancer, 26(2), 227-239. Bioscientifica Ltd
Carlsen, E A, Fazio, N, Granberg, D, Grozinsky-Glasberg, S, Ahmadzadehfar, H, Grana, C M, Zandee, W T, Cwikla, J, Walter, M A, Oturai, P S, Rinke, A, Weaver, A, Frilling, A, Gritti, S, Arveschoug, A K, Meirovitz, A, Knigge, U & Sorbye, H 2019, ' Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : A multicenter cohort study ', Endocrine-Related Cancer, vol. 26, no. 2, pp. 227-239 . https://doi.org/10.1530/ERC-18-0424
Carlsen, E A, Fazio, N, Granberg, D, Grozinsky-Glasberg, S, Ahmadzadehfar, H, Grana, C M, Zandee, W T, Cwikla, J, Walter, M A, Oturai, P S, Rinke, A, Weaver, A, Frilling, A, Gritti, S, Arveschoug, A K, Meirovitz, A, Knigge, U & Sorbye, H 2019, ' Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : a multicenter cohort study ', Endocrine-Related Cancer, vol. 26, no. 2, pp. 227-239 . https://doi.org/10.1530/ERC-18-0424
Endocrine-Related Cancer, 26(2), 227-239. Bioscientifica Ltd
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is largely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54c96900e89eed0fff9cc3e89583c6d
https://hdl.handle.net/1956/22227
https://hdl.handle.net/1956/22227
Autor:
M Heetfeld, C N Chougnet, I H Olsen, A Rinke, I Borbath, G Crespo, J Barriuso, M Pavel, D O'Toole, T Walter
Publikováno v:
Endocrine-Related Cancer, Vol. 22, no. 4, p. 657-664 (2015)
Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are limited. We retrospectively study patients with NET G3 and NEC from eight European centers. D
Autor:
Jennifer A. Chan, Larry K. Kvols, Tiffany Campos, Matthew H. Kulke, Thomas A. Abrams, Jeffrey A. Meyerhardt, Jill Weber, Jonathan R. Strosberg, Eileen Regan, Charles S. Fuchs, Rachel Brady, David P. Ryan
Publikováno v:
Endocrine-Related Cancer. 20:383-390
The IGF pathway has been implicated in the regulation of neuroendocrine tumor (NET) growth, and preliminary studies suggested that ganitumab (AMG 479), a human MAB against IGF1R, may have antitumor activity in this setting. We performed a two-cohort
Autor:
Marianne Pavel, Katharina Detjen, Henning Jann, Tabea Neumann, Georg Hilfenhaus, Andreas Göhrig, Ulrich-Frank Pape, Dietmar Zdunek, Jean Marie Stassen, Georg Hess, Christian Fischer, Bertram Wiedenmann
Publikováno v:
Endocrine-Related Cancer. 20:305-319
Placental growth factor (PlGF), a VEGF-homolog implicated in tumor angiogenesis and adaptation to antiangiogenic therapy, is emerging as candidate target in malignancies. Here, we addressed the expression, function, and prognostic value of PlGF in ne
Autor:
Chiara Cappelletti, Marco F. Manzoni, Cecilia Piani, Paolo Giorgio Arcidiacono, Emanuele Bosi, Luca Albarello, Alessandro Zerbi, Giulia M. Franchi, Marina Scavini
Publikováno v:
Endocrine Related Cancer. 15:175-181
The cytological Ki-67 expression measured on cytological samples collected by endoscopic ultrasonography-guided fine needle aspiration cytology (EUS-FNAC) may provide pre-operative indications for pancreatic endocrine tumours (PETs) management. The a